The drug targets changes in the FGFR3 gene that drive tumour growth in about 10%-20% of these patients. Associate Professor, Ben Tran, a medical oncologist at Peter McCallum Cancer Centre in ...

Overexpression of fibroblast growth factor receptor 3 (FGFR3) has been shown to drive oncogenesis in a subset of patients with multiple myeloma. However, epithelial cancers — such as bladder ...

A year earlier ImmunoGen revealed that the alliance had yielded three candidates, including one ADC directed at fibroblast growth factor receptor 3 (FGFR3) associated with bladder and brain ...

Insilico Medicine Inc. has synthesized fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer.

The drug targets changes in the FGFR3 gene that drive tumor growth in about 10%-20% of these patients. Associate Professor, Ben Tran, a medical oncologist at Peter McCallum Cancer Centre in ...

Tyra Biosciences (NASDAQ:TYRA) is gearing up to report data from its phase 1/2 study, using its FGFR3-inhibitor TYRA-300 for the treatment of patients with urothelial carcinoma and solid tumors.

Specifically, the indication covers eligible patients harboring susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations, who have previously received at least one line of ...

Tasurgratinib (also known as E-7090) is an oral selective FGFR1, FGFR2, and FGFR3 inhibitor that, if approved, will join other drugs in the class on the market, including Incyte’s Pemazyre ...

The drug targets changes in the FGFR3 gene that drive tumor growth in about 10%-20% of these patients. Associate Professor, Ben Tran, a medical oncologist at Peter McCallum Cancer Centre in ...